Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Healthy Adult Participants in Brazil
NCT07518121Phase 1Not yet recruiting
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Aug 2026
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Observed Plasma Concentration and 3 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07518121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518121.